Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7

Monosomy 7 (−7) occurs in various types of paediatric myeloid disorders and has a poor prognosis. Recent studies have demonstrated that patients with germline gain‐of‐function SAMD9/9L variants and loss‐of‐function GATA2 variants are prone to developing myelodysplastic syndrome (MDS) associated with −7. However, the prevalence of the genetic variants among paediatric haematologic disorders with −7 is unknown. The present study screened germline variants of GATA2 and SAMD9/9L in 25 patients with various types of paediatric haematological disorders associated with −7. The diagnoses of the 25 patients included MDS (n = 10), acute myeloid leukaemia (AML) and myeloid sarcomas (n = 9), juvenile myelomonocytic leukaemia (n = 3) and other disorders (n = 3). Seven patients with a germline pathogenic GATA2 variant were found. For SAMD9/9L screening, next‐generation sequencing was used to detect low‐abundance variants and found four novel germline variants. Functional analysis revealed that three out of the four variants showed growth‐restricting capacity in vitro and thus, were judged to be pathogenic. Cases with GATA2 mutation tended to be older, compared to those with SAMD9/9L mutations. In conclusion, GATA2 and SAMD9/9L were sequenced in 25 patients with paediatric haematologic disorders associated with −7, and 40% of them were found to have some pathogenic germline variants in the three genes.

[1]  F. Solé,et al.  Germline loss-of-function SAMD9 and SAMD9L alterations in adult myelodysplastic syndromes. , 2018, Blood.

[2]  M. Loh,et al.  Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes. , 2018, JCI insight.

[3]  Hiroaki Honda,et al.  The enigma of monosomy 7. , 2018, Blood.

[4]  J. Soulier,et al.  A landscape of germ line mutations in a cohort of inherited bone marrow failure patients. , 2018, Blood.

[5]  W. Ji,et al.  A novel SAMD9 mutation causing MIRAGE syndrome: An expansion and review of phenotype, dysmorphology, and natural history , 2018, American journal of medical genetics. Part A.

[6]  M. Boerries,et al.  Constitutional SAMD9L mutations cause familial myelodysplastic syndrome and transient monosomy 7 , 2017, Haematologica.

[7]  M. Schuelke,et al.  Two patients with MIRAGE syndrome lacking haematological features: role of somatic second-site reversion SAMD9 mutations , 2017, Journal of Medical Genetics.

[8]  Melanie Boerries,et al.  RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia , 2017, Nature Communications.

[9]  E. Koonin,et al.  The complex domain architecture of SAMD9 family proteins, predicted STAND-like NTPases, suggests new links to inflammation and apoptosis , 2017, Biology Direct.

[10]  S. Raimondi,et al.  Germline SAMD9 Mutation in Siblings with Monosomy 7 and Myelodysplastic Syndrome , 2017, Leukemia.

[11]  T. Fioretos,et al.  Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. , 2017, Blood.

[12]  J. Klco,et al.  The genomic landscape of pediatric myelodysplastic syndromes , 2016, Nature Communications.

[13]  Deborah Nickerson,et al.  Ataxia-Pancytopenia Syndrome Is Caused by Missense Mutations in SAMD9L. , 2016, American journal of human genetics.

[14]  H. Okano,et al.  SAMD9 mutations cause a novel multisystem disorder, MIRAGE syndrome, and are associated with loss of chromosome 7 , 2016, Nature Genetics.

[15]  M. Wlodarski,et al.  Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. , 2016, Blood.

[16]  K. Okamura,et al.  Human genetic variation database, a reference database of genetic variations in the Japanese population , 2016, Journal of Human Genetics.

[17]  T. Golub,et al.  The Genomic Landscape of Juvenile Myelomonocytic Leukemia , 2015, Nature Genetics.

[18]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[19]  S. Kojima,et al.  Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation , 2014, International Journal of Hematology.

[20]  Takahisa Kawaguchi,et al.  Large-Scale East-Asian eQTL Mapping Reveals Novel Candidate Genes for LD Mapping and the Genomic Landscape of Transcriptional Effects of Sequence Variants , 2014, PloS one.

[21]  J. D. Engel,et al.  A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. , 2014, Cancer cell.

[22]  Britta A. M. Bouwman,et al.  A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia , 2014, Cell.

[23]  T. Suda,et al.  Haploinsufficiency of SAMD9L, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7. , 2013, Cancer cell.

[24]  Sahar Mansour,et al.  Mutations in GATA2 cause primary lymphedema associated with a predisposition to acute myeloid leukemia (Emberger syndrome) , 2011, Nature Genetics.

[25]  Bernard Keavney,et al.  Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. , 2011, Blood.

[26]  Smita Y. Patel,et al.  Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. , 2011, Blood.

[27]  Anna L. Brown,et al.  Heritable GATA2 Mutations Associated with Familial Myelodysplastic Syndrome and Acute Myeloid Leukemia , 2011, Nature Genetics.

[28]  K. Döhner,et al.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  Hans Martin,et al.  Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease , 2010, Nature Medicine.

[30]  T. Inaba,et al.  Identification of a common microdeletion cluster in 7q21.3 subband among patients with myeloid leukemia and myelodysplastic syndrome. , 2009, Biochemical and biophysical research communications.

[31]  S. Raimondi,et al.  Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. , 2007, Blood.

[32]  J. Harbott,et al.  Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. , 2003, Blood.

[33]  M. Slovak,et al.  Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study , 2000 .

[34]  J. Harbott,et al.  Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7 , 1999, Leukemia.

[35]  J. Ihle,et al.  Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Y. Bonny,et al.  Monosomy 7 syndrome. , 1981, The New England journal of medicine.

[37]  S. Hunger,et al.  Monosomy 7 associated with pediatric acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): successful management by allogeneic hematopoietic stem cell transplant (HSCT) , 2005, Bone Marrow Transplantation.